ClinicalTrials.govpublic full text
Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)
dlbcl, tislelizumab, pemetrexed, relapsed or refractory primary diffuse large b-cell lymphoma, r/r primary dlbcl, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 892830
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.